Evidence map›Paper›PMID 36478917›Full record

ArticleERJ open research2022

Eradication of early MRSA infection in cystic fibrosis: a novel study design for the STAR-ter trial.

Fiona Cunningham, Ellen Caldwell, Nicole Mayer-Hamblett, Christopher H Goss, Marianne S Muhlebach

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ERJ open research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Molecular epidemiology ofFrontiers in cellular and infection microbiology · 2026
    Article
  2. Evaluation of Methicillin-ResistantThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2025
    Article
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Fiona CunninghamDivision of Pediatric Pulmonary Medicine, Dept of Pediatrics, University of North Carolina, Chapel Hill, NC, USA.
Ellen CaldwellDivision of Pulmonary and Sleep Medicine, Dept of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA.
Nicole Mayer-HamblettDivision of Pulmonary and Sleep Medicine, Dept of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA.
Christopher H GossDivision of Pulmonary and Sleep Medicine, Dept of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA.
Marianne S MuhlebachDivision of Pediatric Pulmonary Medicine, Dept of Pediatrics, University of North Carolina, Chapel Hill, NC, USA.ORCID https://orcid.org/0000-0001-6391-1598
University of Washington · USUniversity of North Carolina at Chapel Hill · US

Funding

Translational Research Center to Expedite Novel Therapies in Cystic FibrosisP30DK089507 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · PI Christopher Hooper Goss, Lucas R Hoffman · 2010 to 2026
$21.4M
NIDDK NIH HHS P30 DK089507
6 · The paper itself

Abstract

Introduction: Early eradication of methicillin-resistant Methods: Subjects with cystic fibrosis with incident MRSA infection were enrolled into the Discussion: An innovative approach to address a clinical question for a rare event in an orphan disease, cystic fibrosis, is presented to enhance current clinical evidence to guide cystic fibrosis care in relation to new MRSA infection.

Identifiers

PMID36478917
PMCPMC9720546
OpenAlexW4302307284

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.